Literature DB >> 22396438

Management of ovarian cancer: a 75-year-old woman who has completed treatment.

Panagiotis A Konstantinopoulos1, Christopher S Awtrey.   

Abstract

Ovarian cancer includes primary tumors of epithelial, sex cord-stromal, or germ cell origin as well as metastatic tumors that frequently originate in the gastrointestinal tract. Approximately 90% of ovarian cancer is epithelial in origin and constitutes a major therapeutic challenge because of its advanced stage of presentation in most patients. Epithelial ovarian cancer is the most lethal gynecologic malignancy and the fifth most common cause of female cancer death in the United States, with approximately 1 in 70 women developing this disease in their lifetime. Several important advances in surgical and medical management of this disease have led to prolongation of survival and improvement of quality of life of patients with ovarian cancer. Using the case of Ms W, we discuss the signs, symptoms, risk factors, and prognostic factors of epithelial ovarian cancer; review the evidence for surgical and postoperative medical management; and present the current recommendations for screening and follow-up.

Entities:  

Mesh:

Year:  2012        PMID: 22396438     DOI: 10.1001/jama.2012.269

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  7 in total

1.  Begin with a text: teaching the poetics of medicine.

Authors:  Catherine Belling
Journal:  J Med Humanit       Date:  2013-12

2.  A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.

Authors:  Raphael Ceccaldi; Kevin W O'Connor; Kent W Mouw; Adam Y Li; Ursula A Matulonis; Alan D D'Andrea; Panagiotis A Konstantinopoulos
Journal:  Cancer Res       Date:  2015-01-29       Impact factor: 12.701

Review 3.  Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.

Authors:  Panagiotis A Konstantinopoulos; Raphael Ceccaldi; Geoffrey I Shapiro; Alan D D'Andrea
Journal:  Cancer Discov       Date:  2015-10-13       Impact factor: 39.397

4.  Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer.

Authors:  Derin B Keskin; Panagiotis A Konstantinopoulos; Min Liu; Nabihah Tayob; Livius Penter; MacLean Sellars; Anna Tarren; Vipheaviny Chea; Isabel Carulli; Teddy Huang; Shuqiang Li; Su-Chun Cheng; Phuong Le; Laura Frackiewicz; Julia Fasse; Courtney Qi; Joyce F Liu; Elizabeth H Stover; Jennifer Curtis; Kenneth J Livak; Donna Neuberg; Guanglan Zhang; Ursula A Matulonis; Catherine J Wu
Journal:  Clin Cancer Res       Date:  2022-08-02       Impact factor: 13.801

5.  Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.

Authors:  Mei Zeng; Nicholas P Kwiatkowski; Tinghu Zhang; Behnam Nabet; Mousheng Xu; Yanke Liang; Chunshan Quan; Jinhua Wang; Mingfeng Hao; Sangeetha Palakurthi; Shan Zhou; Qing Zeng; Paul T Kirschmeier; Khyati Meghani; Alan L Leggett; Jun Qi; Geoffrey I Shapiro; Joyce F Liu; Ursula A Matulonis; Charles Y Lin; Panagiotis A Konstantinopoulos; Nathanael S Gray
Journal:  Elife       Date:  2018-11-13       Impact factor: 8.140

6.  LncRNA NEAT1 promotes proliferation of ovarian cancer cells and angiogenesis of co-incubated human umbilical vein endothelial cells by regulating FGF9 through sponging miR-365: An experimental study.

Authors:  Jialing Yuan; Ke Yi; Lingyun Yang
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

Review 7.  Current status and evolution of preclinical drug development models of epithelial ovarian cancer.

Authors:  Panagiotis A Konstantinopoulos; Ursula A Matulonis
Journal:  Front Oncol       Date:  2013-12-11       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.